CGN Advisors LLC Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

CGN Advisors LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,661 shares of the medical research company’s stock after selling 1,119 shares during the quarter. CGN Advisors LLC’s holdings in Charles River Laboratories International were worth $1,599,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CRL. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares during the period. Marshall Wace LLP boosted its position in shares of Charles River Laboratories International by 24.6% during the 2nd quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock worth $170,615,000 after purchasing an additional 163,056 shares in the last quarter. 1832 Asset Management L.P. acquired a new position in shares of Charles River Laboratories International during the 2nd quarter worth $33,053,000. Finally, Earnest Partners LLC boosted its holdings in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the company. William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Robert W. Baird cut their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. Finally, Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $209.00.

Insider Buying and Selling

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 1.2 %

Charles River Laboratories International stock opened at $163.77 on Friday. The company’s 50-day moving average price is $190.64 and its two-hundred day moving average price is $198.44. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $160.85 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.72 earnings per share. On average, analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).